Diagnostics, companion diagnostics, and next generation testing
Cell, gene, and regenerative medicine therapies
Orphan, rare disease, specialty treatments
Orphan, rare disease, and specialty treatments face special value demonstration challenges. These include uncertainty around supporting evidence, evolving Health Technology Assessment (HTA) scrutiny, and growing commercial and policy hurdles. Evidera has partnered with orphan drug manufacturers on more than 100 projects to optimize their value proposition. We have helped align access and commercial efforts to changing requirements for this growing category.
Immunotherapies, novel biologics, and therapeutic vaccines
Medical devices and combination products
An important challenge facing devices is ensuring that value demonstration is aligned to optimize market access and return on investment, without being over-engineered. Evidera has more than 30 years of experience in health economics, outcomes research, and market access for medical technology. Our staff has helped leading device manufacturers develop “first” value dossiers, creatively address common evidence gaps, and navigate global reimbursement challenges in a manner that “fits” medical devices.